IHE vs IXJ: Which Popular Healthcare ETF Is the Better Buy for Investors?

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Stock Advisor's total average return is 900%, compared to 207% for the S&P 500, as of July 18, 2026.

  60% confidence

• The Motley Fool Stock Advisor analyst team identified 10 best stocks to buy now, and iShares Global Healthcare ETF was not among them.

  60% confidence

• Cory Renauer has no position in any of the stocks mentioned.

  60% confidence

• IHE's outsized recent gains are largely due to the success of GLP-1 weight-loss drugs, making it vulnerable to competition from lower-cost biosimilars.

  60% confidence

• IXJ is less likely to underperform due to a single issue because of its exposure to insurance companies and medical technology manufacturers.

  60% confidence

• Investors looking to diversify their holdings probably want to avoid the iShares U.S. Pharmaceuticals ETF because its benchmark index is heavily weighted toward Johnson & Johnson and Eli Lilly.

  60% confidence

• The Motley Fool has positions in and recommends AbbVie, Bristol Myers Squibb, and Eli Lilly, and recommends Johnson & Johnson.

  60% confidence

Data points we hold from this source